Amgen (AMGN) ROIC: History & Chart

Name: Amgen Inc. (AMGN) Return on Invested Capital (ROIC) — historical time series
Creator: TGMCharts

Compare

Amgen Inc.(AMGN)

Drug Manufacturers - General · Thousand Oaks, CA

$393.17+0.00 (+0.00%)

Delayed quote: Sep 8, 2026, 4:00 PM EDT

Compare

About Amgen Inc.

Amgen Inc., established in 1980 and headquartered in Thousand Oaks, California, is a global biotechnology leader focused on discovering, developing, manufacturing, and delivering groundbreaking human medicines. The company's scientific endeavors span several critical therapeutic categories, including inflammatory conditions, oncology and hematology, bone health, cardiovascular diseases, nephrology, and neuroscience. Its extensive portfolio features a range of significant pharmaceutical products. Notable examples include Enbrel, prescribed for conditions like plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta, which helps cancer patients by reducing the risk of infection linked to a low white blood cell count; Prolia, utilized in postmenopausal women to combat osteoporosis; and Xgeva, designed to prevent skeletal-related complications. Otezla offers relief for adult patients suffering from plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease. Aranesp addresses anemia and low red blood cell counts, while KYPROLIS is employed to treat patients with relapsed or refractory multiple myeloma. Furthermore, Repatha plays a vital role in lowering the incidence of major cardiovascular events such as myocardial infarction, stroke, and coronary revascularization. Amgen's comprehensive product lineup also encompasses Nplate, Vectibix, MVASI, Parsabiv, EPOGEN, KANJINTI, BLINCYTO, Aimovig, EVENITY, AMGEVITATM, Sensipar/Mimpara, NEUPOGEN, IMLYGIC, Corlanor, and AVSOLA. The company distributes its therapies worldwide, primarily serving healthcare providers, including physicians and their clinics, dialysis centers, hospitals, and pharmacies. Distribution is facilitated through pharmaceutical wholesale distributors, complemented by direct-to-consumer channels. Amgen actively engages in strategic collaborations. It has partnered with entities such as Novartis Pharma AG, UCB, Bayer HealthCare LLC, BeiGene, Ltd., Eli Lilly and Company, Datos Health, and Verastem, Inc., to jointly assess VS-6766 when combined with lumakrastm (Sotorasib) in patients with KRAS G12C-mutant non-small cell lung cancer. Another key alliance involves Kyowa Kirin Co., Ltd., for the co-development and commercialization of KHK4083, a Phase 3-ready anti-OX40 fully human monoclonal antibody targeting atopic dermatitis and other autoimmune conditions. Additionally, Amgen maintains research and development partnerships with Neumora Therapeutics, Inc. and Plexium, Inc.

Thousand Oaks, CA

31,500 employees

www.amgen.com

Healthcare / Drug Manufacturers - General

Sector: Healthcare
Industry: Drug Manufacturers - General
CEO: Robert A. Bradway

View full financials

AMGN Return on Invested Capital (ROIC) Metrics

RETURN ON INVESTED CAPITAL (ROIC)

14.22%

RETURN ON INVESTED CAPITAL (ROIC) AVG TTM

12.33%

RETURN ON INVESTED CAPITAL (ROIC) AVG 3Y

10.18%

RETURN ON INVESTED CAPITAL (ROIC) AVG 5Y

11.77%

RETURN ON INVESTED CAPITAL (ROIC) AVG 10Y

12.45%

RETURN ON INVESTED CAPITAL (ROIC) AVG 15Y

11.59%

RETURN ON INVESTED CAPITAL (ROIC) AVG 20Y

11.63%

CURRENT VS TTM AVG

+15.38%

CURRENT VS 3Y AVG

+39.68%

CURRENT VS 5Y AVG

+20.88%

CURRENT VS 10Y AVG

+14.19%

CURRENT VS 15Y AVG

+22.74%

CURRENT VS 20Y AVG

+22.24%

SECTOR MEDIAN · HEALTHCARE

8.75%

median of 90 covered companies

CURRENT VS SECTOR MEDIAN

+62.64%

vs the sector median at left

NAME	MARKET CAP	RETURN ON INVESTED CAPITAL (ROIC)	TTM	3Y	5Y
Amgen Inc. (AMGN)	$212.20B	14.22%	12.33%	10.18%	11.77%
Novo Nordisk A/S (NVO)vs ›	$200.54B	30.21%	34.36%	43.28%	43.42%
Thermo Fisher Scientific Inc. (TMO)vs ›	$224.09B	7.44%	7.81%	8.16%	9.11%
Abbott Laboratories (ABT)vs ›	$182.59B	6.07%	9.16%	9.70%	9.86%
Gilead Sciences, Inc. (GILD)vs ›	$182.06B	-3.66%	11.34%	11.28%	10.29%
AstraZeneca PLC (AZN)vs ›	$248.20B	12.83%	11.72%	9.44%	7.92%
Pfizer Inc. (PFE)vs ›	$158.39B	9.33%	9.06%	10.61%	10.43%
Danaher Corporation (DHR)vs ›	$144.25B	5.03%	5.92%	6.55%	6.70%
Vertex Pharmaceuticals Incorporated (VRTX)vs ›	$134.24B	17.33%	8.72%	13.98%	17.04%
Bristol-Myers Squibb Company (BMY)vs ›	$132.14B	15.47%	14.35%	12.24%	10.38%

NAME

MARKET CAP

RETURN ON INVESTED CAPITAL (ROIC)

TTM

Amgen Inc. (AMGN)

$212.20B

14.22%

12.33%

10.18%

11.77%

Novo Nordisk A/S (NVO)vs ›

$200.54B

30.21%

34.36%

43.28%

43.42%

Thermo Fisher Scientific Inc. (TMO)vs ›

$224.09B

7.44%

7.81%

8.16%

9.11%

Abbott Laboratories (ABT)vs ›

$182.59B

6.07%

9.16%

9.70%

9.86%

Gilead Sciences, Inc. (GILD)vs ›

$182.06B

-3.66%

11.34%

11.28%

10.29%

AstraZeneca PLC (AZN)vs ›

$248.20B

12.83%

11.72%

9.44%

7.92%

Pfizer Inc. (PFE)vs ›

$158.39B

9.33%

9.06%

10.61%

10.43%

Danaher Corporation (DHR)vs ›

$144.25B

5.03%

5.92%

6.55%

6.70%

Vertex Pharmaceuticals Incorporated (VRTX)vs ›

$134.24B

17.33%

8.72%

13.98%

17.04%

Bristol-Myers Squibb Company (BMY)vs ›

$132.14B

15.47%

14.35%

12.24%

10.38%

Return on Invested Capital (ROIC) Formula & Definition

ROIC = NOPAT / Invested Capital, where NOPAT = Operating Income × (1 − effective tax rate) and Invested Capital = Total Assets − (Current Liabilities − Short-Term Debt)

Return on invested capital measures the after-tax operating return a company earns on the capital invested in the business. TGMCharts computes it from reported statements: trailing-twelve-month operating income after tax, over invested capital at the latest balance sheet — total assets less the non-interest-bearing current liabilities (payables, accruals, deferred revenue) that fund them; short-term debt stays in the capital base. The tax rate is the period's own effective rate (income tax ÷ pretax income), capped at 45%; when pretax income is zero or negative, or the tax line is a net benefit, no tax is deducted — the operating figure is shown untaxed rather than adjusted by an assumed rate. Not shown for banks, insurers or funds.

Return on Invested Capital (ROIC) FAQ

What is the return on invested capital (ROIC) for Amgen Inc. (AMGN)?

The return on invested capital (ROIC) for AMGN stock is 14.22%.

Is Amgen Inc.'s return on invested capital (ROIC) high or low?

The return on invested capital (ROIC) of 14.22% is 21% above its 5-year average of 11.77%, around the middle of its 5-year range (7.34%–17.29%).

What is the TTM average return on invested capital (ROIC) for Amgen Inc. (AMGN)?

The TTM average return on invested capital (ROIC) for AMGN stock is 12.33%.

What is the 3Y average return on invested capital (ROIC) for Amgen Inc. (AMGN)?

The 3Y average return on invested capital (ROIC) for AMGN stock is 10.18%.

What is the 5Y average return on invested capital (ROIC) for Amgen Inc. (AMGN)?

The 5Y average return on invested capital (ROIC) for AMGN stock is 11.77%.

What is the 10Y average return on invested capital (ROIC) for Amgen Inc. (AMGN)?

The 10Y average return on invested capital (ROIC) for AMGN stock is 12.45%.

What is the 15Y average return on invested capital (ROIC) for Amgen Inc. (AMGN)?

The 15Y average return on invested capital (ROIC) for AMGN stock is 11.59%.

What is the 20Y average return on invested capital (ROIC) for Amgen Inc. (AMGN)?

The 20Y average return on invested capital (ROIC) for AMGN stock is 11.63%.

DATE	RETURN ON INVESTED CAPITAL (ROIC)
2026-06-30	14.22%
2026-03-31	13.85%
2025-12-31	12.68%
2025-09-30	10.44%
2025-06-30	10.44%
2025-03-31	9.53%
2024-12-31	8.91%
2024-09-30	7.58%
2024-06-30	7.34%
2024-03-31	7.81%
2023-12-31	8.42%
2023-09-30	10.21%
2023-06-30	10.94%
2023-03-31	10.36%
2022-12-31	16.72%
2022-09-30	16.74%
2022-06-30	17.29%
2022-03-31	14.91%
2021-12-31	13.69%
2021-09-30	11.74%
2021-06-30	13.25%
2021-03-31	15.47%
2020-12-31	15.88%
2020-09-30	14.95%
2020-06-30	14.81%
2020-03-31	16.05%
2019-12-31	16.66%
2019-09-30	17.00%
2019-06-30	16.61%
2019-03-31	15.90%
2018-12-31	15.74%
2018-09-30	9.29%
2018-06-30	9.27%
2018-03-31	8.84%
2017-12-31	7.61%
2017-09-30	11.66%
2017-06-30	11.85%
2017-03-31	11.83%
2016-12-31	11.65%
2016-09-30	11.13%
2016-06-30	11.36%
2016-03-31	11.10%
2015-12-31	11.31%
2015-09-30	10.48%
2015-06-30	9.59%
2015-03-31	9.90%
2014-12-31	9.15%
2014-09-30	8.41%
2014-06-30	8.75%
2014-03-31	8.69%
2013-12-31	9.33%
2013-09-30	10.35%
2013-06-30	10.70%
2013-03-31	10.98%
2012-12-31	9.95%
2012-09-30	9.97%
2012-06-30	9.04%
2012-03-31	9.22%
2011-12-31	8.86%
2011-09-30	9.51%
2011-06-30	10.93%
2011-03-31	12.25%
2010-12-31	12.25%
2010-09-30	11.86%
2010-06-30	13.11%
2010-03-31	13.80%
2009-12-31	13.63%
2009-09-30	13.08%
2009-06-30	12.93%
2009-03-31	12.28%
2008-12-31	12.80%
2008-09-30	12.27%
2008-06-30	9.81%
2008-03-31	9.90%
2007-12-31	10.44%
2007-09-30	10.72%
2007-06-30	13.86%
2007-03-31	10.65%
2006-12-31	9.84%
2006-09-30	10.09%
2006-06-30	10.02%
2006-03-31	13.50%
2005-12-31	14.24%
2005-09-30	13.70%
2005-06-30	11.26%
2005-03-31	10.32%
2004-12-31	8.88%
2004-09-30	8.89%
2004-06-30	10.67%
2004-03-31	9.97%
2003-12-31	9.28%
2003-09-30	29.26%
2003-06-30	28.52%

DATE

RETURN ON INVESTED CAPITAL (ROIC)

2026-06-30

14.22%

2026-03-31

13.85%

2025-12-31

12.68%

2025-09-30

10.44%

2025-06-30

10.44%

2025-03-31

9.53%

2024-12-31

8.91%

2024-09-30

7.58%

2024-06-30

7.34%

2024-03-31

7.81%

2023-12-31

8.42%

2023-09-30

10.21%

2023-06-30

10.94%

2023-03-31

10.36%

2022-12-31

16.72%

2022-09-30

16.74%

2022-06-30

17.29%

2022-03-31

14.91%

2021-12-31

13.69%

2021-09-30

11.74%

2021-06-30

13.25%

2021-03-31

15.47%

2020-12-31

15.88%

2020-09-30

14.95%

2020-06-30

14.81%

2020-03-31

16.05%

2019-12-31

16.66%

2019-09-30

17.00%

2019-06-30

16.61%

2019-03-31

15.90%

2018-12-31

15.74%

2018-09-30

9.29%

2018-06-30

9.27%

2018-03-31

8.84%

2017-12-31

7.61%

2017-09-30

11.66%

2017-06-30

11.85%

2017-03-31

11.83%

2016-12-31

11.65%

2016-09-30

11.13%

2016-06-30

11.36%

2016-03-31

11.10%

2015-12-31

11.31%

2015-09-30

10.48%

2015-06-30

9.59%

2015-03-31

9.90%

2014-12-31

9.15%

2014-09-30

8.41%

2014-06-30

8.75%

2014-03-31

8.69%

2013-12-31

9.33%

2013-09-30

10.35%

2013-06-30

10.70%

2013-03-31

10.98%

2012-12-31

9.95%

2012-09-30

9.97%

2012-06-30

9.04%

2012-03-31

9.22%

2011-12-31

8.86%

2011-09-30

9.51%

2011-06-30

10.93%

2011-03-31

12.25%

2010-12-31

12.25%

2010-09-30

11.86%

2010-06-30

13.11%

2010-03-31

13.80%

2009-12-31

13.63%

2009-09-30

13.08%

2009-06-30

12.93%

2009-03-31

12.28%

2008-12-31

12.80%

2008-09-30

12.27%

2008-06-30

9.81%

2008-03-31

9.90%

2007-12-31

10.44%

2007-09-30

10.72%

2007-06-30

13.86%

2007-03-31

10.65%

2006-12-31

9.84%

2006-09-30

10.09%

2006-06-30

10.02%

2006-03-31

13.50%

2005-12-31

14.24%

2005-09-30

13.70%

2005-06-30

11.26%

2005-03-31

10.32%

2004-12-31

8.88%

2004-09-30

8.89%

2004-06-30

10.67%

2004-03-31

9.97%

2003-12-31

9.28%

2003-09-30

29.26%

2003-06-30

28.52%

Return on Invested Capital (ROIC): 14.22%

AMGN Return on Invested Capital (ROIC)

AMGN Average Return on Invested Capital (ROIC) Chart

AMGN Current vs Average Return on Invested Capital (ROIC) Chart

AMGN Return on Invested Capital (ROIC) Metrics

AMGN Competitors' Return on Invested Capital (ROIC)

Capital Efficiency

Return on Invested Capital (ROIC) Formula & Definition

Return on Invested Capital (ROIC) FAQ

AMGN Return on Invested Capital (ROIC) History

Related Metrics